Holen Sie sich die Stockscreener-App
30.88
5.64%
1.65
Handel nachbörslich:
30.76
-0.12
-0.39%
Schlusskurs vom Vortag:
$29.23
Offen:
$29.61
24-Stunden-Volumen:
1.64M
Relative Volume:
1.49
Marktkapitalisierung:
$12.92B
Einnahmen:
$6.18B
Nettoeinkommen (Verlust:
$626.40M
KGV:
21.52
EPS:
1.435
Netto-Cashflow:
$848.81M
1W Leistung:
+6.15%
1M Leistung:
+12.29%
6M Leistung:
-5.68%
1J Leistung:
-16.92%
1-Tages-Spanne:
$29.60
$30.89
1-Wochen-Bereich:
$28.69
$30.89
52-Wochen-Spanne:
$26.12
$37.51
Smith Nephew Plc Adr Stock (SNN) Company Profile
Firmenname
Smith Nephew Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare SNN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
30.88 | 12.92B | 6.18B | 626.40M | 848.81M | 1.435 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2026-09-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-08-31 | Eingeleitet | BTIG Research | Neutral |
| 2026-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-08-05 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2026-06-04 | Herabstufung | Kepler | Buy → Hold |
| 2025-12-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-14 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-03-12 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-06 | Herabstufung | Berenberg | Buy → Hold |
| 2024-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-10-13 | Eingeleitet | Stifel | Hold |
| 2023-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2023-04-27 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Eingeleitet | Citigroup | Buy |
| 2022-11-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-04 | Hochstufung | Redburn | Sell → Neutral |
| 2021-06-09 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Eingeleitet | Barclays | Overweight |
| 2020-07-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-21 | Eingeleitet | Citigroup | Buy |
| 2019-11-12 | Eingeleitet | Bernstein | Outperform |
| 2019-07-23 | Hochstufung | Berenberg | Hold → Buy |
| 2019-02-08 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-27 | Herabstufung | Goldman | Buy → Neutral |
| 2017-01-19 | Eingeleitet | HSBC Securities | Hold |
| 2016-12-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Herabstufung | Berenberg | Buy → Hold |
| 2016-02-26 | Eingeleitet | Cantor Fitzgerald | Hold |
Alle ansehen
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
REGSmith & Nephew PlcSterling Amount of Dividend - TradingView
SMITH & NEPHEW PLC R (NPW1.HM) Q4 FY2025 earnings call transcript - Yahoo Finance
Smith & Nephew PLC (NPW1.HM) insider ownership and holdings - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) stock historical prices and data - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) valuation measures and financial statistics - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) company profile and facts - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) analyst ratings, estimates and forecasts - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) stock major holders - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) stock price, news, quote and history - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) income statement - Yahoo Finance UK
Smith & Nephew PLC (NPW1.HM) options chain - Yahoo Finance UK
SMITH & NEPHEW PLC R (NPW1.HM) Q2 FY2026 earnings call transcript - Yahoo Finance
Smith & Nephew (NYSE:SNN) Looks Like a Decent Value Stock - ChartMill
NPW1.HM Interactive Stock Chart | SMITH & NEPHEW PLC R Stock - Yahoo Finance
Smith & Nephew SNATS, Inc. (SNN) Stock Forecasts - Yahoo Finance
Smith & Nephew PLC (NPW1.HM) stock price, news, quote and history - Yahoo Finance UK
Blue-Chip Stock Smith & Nephew (LSE:SN.) Cuts Sales Outlook: What It Means - Kalkine Media
Smith & Nephew plc (NPW1.DE) insider ownership and holdings - Yahoo Finance UK
FTSE 100 Smith & Nephew (LSE:SN.): Outlook and Dividend - Kalkine Media
A Look at Smith & Nephew PLC (SNN) After 4.3% Gain -- GF Value $30.88 vs Price $29.09 - GuruFocus
Why Is Smith & Nephew (LSE:SN.) Stock Under Scrutiny After Cutting Its Sales Outlook? - Kalkine Media
SMITH & NEPHEW PLC (SN1N.MX) Q2 FY2026 earnings call transcript - Yahoo Finance
Smith & Nephew plc Completes the Pricing of USD 700,000,000 5.750% Notes Due 2036 - marketscreener.com
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
A November 4 analyst call will follow Smith & Nephew (SNN)'s Q3 trading report. - Stock Titan
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal - GlobeNewswire Inc.
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo. - GlobeNewswire Inc.
A five-year trial found better knee pain relief with a cartilage implant than standard surgery. - Stock Titan
Smith & Nephew Launches CartiHeal Cartilage Repair Implant in Europe - Yahoo Finance
5.150% notes due 2027 are named in Smith & Nephew (NYSE: SNN)'s NYSE removal notice. - Stock Titan
Smith & Nephew PLC's Dividend Analysis - Yahoo Finance
Smith & Nephew stock hits 52-week low at 26.39 USD - Investing.com Nigeria
Smith & Nephew plc Announces Redemption Price of $350,000,000 5.150% Notes Due 2027 - marketscreener.com
837M shares carry votes at Smith & Nephew (SNN). Another 40.3M shares are held in treasury. - Stock Titan
The 5.150% notes due in 2027 will be redeemed by Smith & Nephew (SNN) on October 5. - Stock Titan
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Zacks Investment Research
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Yahoo Finance
AlphaValue/Baader Europe Downgrades Smith & Nephew to Add - marketscreener.com
Smith & Nephew: Estimates reset after guidance cut - marketscreener.com
Smith & Nephew (LSE:SN) Rolls Out EVOS PELVIC This Week: Can It Lift Its Orthopaedic Trauma Game? - Kalkine Media
Smith & Nephew stock faces a Q2 revenue miss - AD HOC NEWS
Smith and Nephew stock falls 0.24 percent ahead of the open - AD HOC NEWS
Smith & Nephew stock trades near its yearly low - AD HOC NEWS
Smith+Nephew Launches the New Evos? Pelvic Plating System - marketscreener.com
One system combines plates, screws and tools for complex pelvic fracture surgery - Stock Titan
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System - markets.businessinsider.com
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical case of LANDMARK◊ Total Knee System - Ortho Spine News
This shoulder implant has been used in more than 250,000 procedures. Smith+Nephew will showcase it. - Stock Titan
Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Unveiling a 19% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
New LSE share admission takes Smith & Nephew (NYSE: SNN) to 877,750,024 shares - Stock Titan
Finanzdaten der Smith Nephew Plc Adr-Aktie (SNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):